{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"4.6","value":"2.8"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"6.4","value":"4.2"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"2.8","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG000","title":"Arm A (CLL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm B (NHL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG002","title":"Arm C (CLL With Richters)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"5 years","title":"Progression-free Survival of Patients Treated in Single Agent Phase","type":"SECONDARY","unitOfMeasure":"Months"}